Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
- PMID: 37040843
- DOI: 10.1016/j.jhep.2023.03.040
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Abstract
Background & aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. We aimed to estimate the pooled global NAFLD incidence.
Methods: We performed a systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline to evaluate the global incidence of ultrasound-diagnosed NAFLD.
Results: A total of 63 eligible studies (1,201,807 persons) were analyzed. Studies were from Mainland China/Hong Kong (n = 26), South Korea (n = 22), Japan (n = 14), other (n = 2, Sri Lanka, Israel); 63.8% were clinical center studies; median study year 2000 to 2016; 87% were good quality. Among the 1,201,807 persons at risk, 242,568 persons developed NAFLD, with an incidence rate of 4,612.8 (95% CI 3,931.5-5,294.2) per 100,000 person-years and no statistically significant differences by study sample size (p = 0.90) or study setting (p = 0.055). Males had higher incidence vs. females (5,943.8 vs. 3,671.7, p = 0.0013). Both the obese (vs. non-obese) and the overweight/obese groups (vs. normal weight) were about threefold more likely to develop NAFLD (8,669.6 vs. 2,963.9 and 8,416.6 vs. 3,358.2, respectively) (both p <0.0001). Smokers had higher incidence than non-smokers (8,043.2 vs. 4,689.7, p = 0.046). By meta-regression, adjusting for study year, study setting, and study location, study period of 2010 or after and study setting were associated with increased incidence (p = 0.010 and p = 0.055, respectively). By country, China had a higher NAFLD incidence compared to non-China regions (p = 0.012) and Japan a lower incidence compared to non-Japan regions (p = 0.005).
Conclusions: NAFLD incidence is increasing with a current estimate of 4,613 new cases per 100,000 person-years. Males and overweight/obese individuals had significantly higher incidence rates compared to females and those of normal weight. Public health interventions for prevention of NAFLD are needed with a special emphasis on males, overweight/obese individuals, and higher risk regions.
Impact and implications: Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of people worldwide and appears to be increasing, but data to estimate the incidence rate are limited. In this meta-analytic study of over 1.2 million people, we estimated an incidence rate of NAFLD of 46.13 per 1,000 person-years with significant differences by sex, BMI, geography, and time-period. As treatment options for NAFLD remain limited, prevention of NAFLD should remain the focus of public health strategies. Studies such as these can help policy makers in determining which and whether their interventions are impactful.
Keywords: cohort studies; epidemiology; metabolic liver disease; risk factors.
Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
NAFLD incidence is increasing.Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):344. doi: 10.1038/s41575-023-00787-y. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37085617 No abstract available.
-
Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again.J Hepatol. 2023 Oct;79(4):e164-e165. doi: 10.1016/j.jhep.2023.04.030. Epub 2023 May 4. J Hepatol. 2023. PMID: 37149226 No abstract available.
-
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis.J Hepatol. 2023 Oct;79(4):e165-e167. doi: 10.1016/j.jhep.2023.05.035. Epub 2023 Jun 12. J Hepatol. 2023. PMID: 37315808 No abstract available.
Similar articles
-
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16. Lancet Gastroenterol Hepatol. 2023. PMID: 36400097
-
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-752. doi: 10.1016/S2468-1253(20)30077-7. Epub 2020 May 12. Lancet Gastroenterol Hepatol. 2020. PMID: 32413340
-
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.Clin Gastroenterol Hepatol. 2022 Mar;20(3):e573-e582. doi: 10.1016/j.cgh.2021.02.030. Epub 2021 Feb 20. Clin Gastroenterol Hepatol. 2022. PMID: 33618024
-
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26. Clin Gastroenterol Hepatol. 2017. PMID: 28554682
-
Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.Hepatol Int. 2019 May;13(3):314-322. doi: 10.1007/s12072-018-9916-4. Epub 2018 Dec 11. Hepatol Int. 2019. PMID: 30539516
Cited by
-
Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.Int J Mol Sci. 2023 Sep 28;24(19):14704. doi: 10.3390/ijms241914704. Int J Mol Sci. 2023. PMID: 37834153 Free PMC article. Review.
-
Ultrasound-derived fat fraction for diagnosing hepatic steatosis: a systematic review and meta-analysis.Eur Radiol. 2025 May 9. doi: 10.1007/s00330-025-11652-8. Online ahead of print. Eur Radiol. 2025. PMID: 40346257
-
Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts.Front Nutr. 2025 May 22;12:1571487. doi: 10.3389/fnut.2025.1571487. eCollection 2025. Front Nutr. 2025. PMID: 40474897 Free PMC article.
-
Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease.Nutrients. 2023 Oct 24;15(21):4507. doi: 10.3390/nu15214507. Nutrients. 2023. PMID: 37960160 Free PMC article.
-
Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks.PLoS One. 2025 Jan 30;20(1):e0316158. doi: 10.1371/journal.pone.0316158. eCollection 2025. PLoS One. 2025. PMID: 39883611 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials